Top Page
SkinBioTherapeutics
(LSE:SBTX)
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
SkinBioTherapeutics Business Overview & Revenue Model
SkinBioTherapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 161.65K | 1.21M | 132.06K | 74.76K | 0.00 | 0.00 | Gross Profit |
| 73.83K | 683.04K | 85.19K | 15.91K | -5.05K | -5.10K | EBIT |
| -3.03M | -2.91M | -3.00M | -2.98M | -1.49M | -1.62M | EBITDA |
| -2.98M | -2.72M | -2.96M | -2.95M | -1.49M | -1.61M | Net Income Common Stockholders |
| -2.88M | -2.88M | -2.84M | -2.79M | -1.43M | -1.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.52M | 800.90K | 1.31M | 1.80M | 4.61M | 2.16M | Total Assets |
| 3.05M | 5.22M | 2.59M | 3.08M | 5.73M | 2.77M | Total Debt |
| 0.00 | 818.74K | 100.65K | 127.86K | 139.85K | 0.00 | Net Debt |
| -2.52M | 17.84K | -1.21M | -1.68M | -4.47M | -2.16M | Total Liabilities |
| 103.39K | 2.25M | 599.34K | 609.61K | 519.67K | 304.83K | Stockholders Equity |
| 2.94M | 2.97M | 1.99M | 2.48M | 5.22M | 2.47M |
| Cash Flow | Free Cash Flow | ||||
| -3.17M | -2.92M | -2.81M | -2.77M | -1.67M | -965.80K | Operating Cash Flow |
| -3.02M | -2.73M | -2.65M | -2.67M | -1.56M | -892.14K | Investing Cash Flow |
| -214.57K | -2.30M | -165.28K | -96.81K | -112.31K | -73.67K | Financing Cash Flow |
| 5.31M | 4.51M | 2.32M | -35.12K | 4.12M | 0.00 |
SkinBioTherapeutics Technical Analysis
SkinBioTherapeutics Peers Comparison
SkinBioTherapeutics Corporate Events
SkinBioTherapeutics plc has appointed Singer Capital Markets as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and market positioning, potentially benefiting stakeholders through improved advisory and brokerage services.
SkinBioTherapeutics PLC, a company involved in the biotechnology sector, has announced a change in its major holdings. The University of Manchester has reduced its voting rights in the company from 3.42% to 2.93%, as of April 29, 2025. This reduction in voting rights could impact the company’s shareholder dynamics and influence future decisions.
SkinBioTherapeutics PLC has announced a change in the breakdown of its voting rights, with Optibiotix Health plc now holding 7.95% of the voting rights, down from a previous 8.46%. This adjustment in voting rights reflects a shift in stakeholder influence within the company, potentially impacting its strategic decisions and governance.
SkinBioTherapeutics announced the exercise of warrants by Macquarie for 1,099,244 ordinary shares at £0.2043 per share, leaving no outstanding warrants with Macquarie. The new shares are expected to be admitted to AIM on May 1, 2025, increasing the total number of issued shares and voting rights to 234,074,627. This development may impact shareholder calculations under the Financial Conduct Authority’s rules, reflecting the company’s strategic financial maneuvers in the skin health industry.
SkinBioTherapeutics has appointed Simon Hewitson as Executive Director and Chief Operating Officer, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and support its growth in the skin health sector, particularly as it continues to expand its product offerings and market reach.
SkinBioTherapeutics plc has announced significant changes in its leadership team, appointing Simon Hewitson as Chief Operating Officer and Emily Bertram as Group Finance Director. These changes aim to strengthen the company’s operational and financial functions amid an active M&A strategy and the launch of Croda Zenakine™. The appointments are expected to support the company’s growth and enhance its market position, with Hewitson’s extensive corporate finance experience and Bertram’s familiarity with the company’s financial systems being key assets.
SkinBioTherapeutics announced the successful global launch of Zenakine™ by Croda Beauty at the in-cosmetics Global 2025 meeting, receiving a standing ovation for its technical presentation. Zenakine™ offers benefits such as improved cell longevity, skin regeneration, and anti-aging effects. Despite the positive reception, the company noted an unexplained drop in share price. The management plans to discuss Zenakine™’s attributes and commercialization at an upcoming investor presentation, highlighting its potential impact on the company’s market position and stakeholder interests.
SkinBioTherapeutics announced that Croda plc has launched Zenakine™, a neuroactive ingredient designed to improve skin health by reducing stress effects and enhancing sleep quality, at the in-cosmetics Global exhibition. This launch marks a significant milestone for SkinBioTherapeutics, as Zenakine™ is the first ingredient with clinical measures on sleep benefits, offering a competitive edge in the cosmetics industry with its multifunctional and sustainable formulation options.
SkinBioTherapeutics PLC has announced a change in its major holdings, with Optibiotix Health plc reducing its voting rights from 9.58% to 8.46%. This adjustment in shareholding reflects a strategic shift and could impact the company’s governance and decision-making processes, potentially influencing its market position and stakeholder interests.
SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 1,000,000 ordinary shares at £0.2043 per share, leaving 1,099,244 warrants outstanding. Following this exercise, the company’s total issued shares and voting rights will increase to 232,975,383, impacting shareholder calculations under the Financial Conduct Authority’s rules.
SkinBioTherapeutics has reported significant revenue growth for the half-year ending December 2024, driven by acquisitions and increased sales of its AxisBiotix product. The company completed the integration of Dermatonics and Bio-Tech Solutions, which contributed to its strengthened financial position. The upcoming global launch of its SkinBiotix lysate by Croda is anticipated to further enhance its market presence. The company is focused on expanding its product offerings and enhancing its operational capabilities, positioning itself for future profitability.
SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 250,000 ordinary shares at £0.2043 per share, increasing the company’s total issued shares to 231,975,383. This development reflects the company’s ongoing efforts to strengthen its financial position and expand its market presence, potentially impacting shareholder interests and enhancing its industry positioning.
SkinBioTherapeutics PLC has announced a change in voting rights following an acquisition or disposal by David Campbell Brierwood, who now holds 5.561% of the company’s voting rights, up from a previous 4.1%. This change in voting rights could potentially impact the company’s shareholder dynamics and influence future decision-making processes.
SkinBioTherapeutics announced the exercise of warrants by David Brierwood, reducing the company’s debt from £950,000 to £600,000 following their acquisition of Bio-Tech Solutions Limited. The new ordinary shares will be admitted to AIM, adjusting the total issued shares to 231,725,383. CEO Stuart Ashman highlighted the successful integration of Bio-Tech Solutions, which aligns with expectations and will contribute to upcoming financial results.